Comparative Pharmacology
Head-to-head clinical analysis: BONTRIL versus BONTRIL PDM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONTRIL versus BONTRIL PDM.
BONTRIL vs BONTRIL PDM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
BONTRIL 50 mg orally once daily, with or without food.
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
None Documented
None Documented
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Category C
Category C
Sympathomimetic Anorectic
Sympathomimetic Anorectic